Entera Bio (ENTX) Fundamental Analysis: Revenue, Earnings & Valuation

0.41 / 10

Underperform

Fundamental analysis rates ENTX as Underperform with a 0.4/10 score. Positive points include fixed‑asset turnover and strong interest‑coverage, but major concerns arise from negative revenue growth, high cost‑of‑sales (100%), low receivables turnover and adverse tax‑to‑profit ratio, indicating weak quality.

Analysis Checks(4/10)

Revenue-MV

Value-0.28

Score1/3

Weight106.64%

1M Return5.06%

Total operating revenue (YoY growth rate %)

Value-57.58

Score2/3

Weight10.69%

1M Return0.58%

Inventory turnover ratio

Value47.57

Score3/3

Weight-11.43%

1M Return-0.67%

Accounts receivable turnover ratio

Value0.67

Score1/3

Weight-28.46%

1M Return-1.57%

PB-ROE

Value3.94

Score0/3

Weight82.70%

1M Return3.80%

Income tax / Total profit (%)

Value-5.52

Score0/3

Weight-25.71%

1M Return-1.54%

Fixed assets turnover ratio

Value0.13

Score2/3

Weight-18.04%

1M Return-1.01%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.64

Score2/3

Weight-12.77%

1M Return-0.73%

Cost of sales ratio (%)

Value100.00

Score1/3

Weight-107.65%

1M Return-7.47%

Asset-MV

Value-0.48

Score0/3

Weight104.02%

1M Return4.88%

Is ENTX undervalued or overvalued?

ENTX scores 0.41/10 on fundamentals and holds a Premium valuation at present. Backed by its -72.26% ROE, -8694.35% net margin, -5.02 P/E ratio, 3.55 P/B ratio, and 7.69% earnings growth, these metrics solidify its Underperform investment rating.